Takeda Will Take TYK2 Inhibitor Into Phase III, Looks For Dosing Edge Over BMS Rival

The Japanese pharma company has bet big on its TYK2 inhibitor, but it must demonstrate competitive safety and efficacy if it is to challenge Bristol Myers Squibb’s first-to-market Sotyktu.

Back in December 2022, Takeda paid out a near-record-breaking $4bn upfront to acquire Nimbus Therapeutics' TYK2 inhibitor, TAK-279 in the expectation that it could be an oral therapy blockbuster for conditions such as psoriasis and psoriatic arthritis. (Also see "Takeda Aims At BMS’s Sotyktu In $4bn Deal For Nimbus’s TYK2 Inhibitor" - Scrip, 13 December, 2022.)

As the company gears up to take TAK-279 in two Phase III studies, whether this was money well

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Boehringer’s Next Generation IPF Drug Underwhelms

 

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By 

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By 

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

More from R&D

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By 

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 

Shares are hit as German conglomerate lowers revenue forecast.